Influenza A virus H1N1 vaccine - iBio/Fraunhofer USA Center for Molecular Biotechnology

Drug Profile

Influenza A virus H1N1 vaccine - iBio/Fraunhofer USA Center for Molecular Biotechnology

Alternative Names: H1N1 vaccine - iBio; H1N1 virus vaccine - iBio; HAC1 vaccine; Influenza A virus H1N1 vaccine - iBio; Swine flu vaccine - iBio

Latest Information Update: 03 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iBio Inc
  • Developer Fraunhofer USA Center for Molecular Biotechnology; iBio Inc
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H1N1 subtype

Most Recent Events

  • 03 May 2016 No recent reports on development identified - Phase-I for Influenza-A virus H1N1 subtype (Prevention) in USA (IM)
  • 21 Mar 2012 Final immunogenicity and adverse event data from a phase I trial in Influenza-A virus H1N1 subtype released by Fraunhofer USA Center for Molecular Biotechnology/iBio ,
  • 03 Jun 2011 Interim immunogenicity and safety data from a preclinical trial in Influenza-A virus H1N1 subtype released by Fraunhofer CMB
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top